PDF(Pubmed)
Abstract：
Antibodies blocking the calcitonin gene-related peptide have revolutionized episodic and chronic migraine treatment. However, their applicability to non-cephalic pain conditions, such as osteoarthritis, is yet unknown. Osteoarthritis remains a clinical challenge, associated with high disability and limited treatment options. Like migraine, neuropeptides including calcitonin gene-related peptides are involved in its pathophysiology. We present the first case of a patient: a 73-year-old female with osteoarthritis who received monthly treatment for her chronic migraine with 140 mg subcutaneous erenumab, a monoclonal antibody against the receptor of calcitonin gene-related peptide. Though the migraine was unresponsive, the patient\'s arthritic symptoms improved drastically during treatment period with erenumab; daily pain decreased from VAS 7 to 2, and walking distance doubled from 1,000 m to 2,000 m. The arthritic symptoms relapsed after discontinuation of erenumab. Erenumab could potentially have beneficial effects on symptoms of osteoarthritis. Future studies investigating these effects are warranted.
摘要：
阻断降钙素基因相关肽的抗体彻底改变了发作性和慢性偏头痛的治疗。然而,它们适用于非头部疼痛的情况，比如骨关节炎，还未知。骨关节炎仍然是一个临床挑战，与高残疾和有限的治疗选择有关。比如偏头痛,神经肽包括降钙素基因相关肽参与其病理生理。我们介绍了第一例患者：一名73岁的女性骨关节炎患者，每月接受140mg皮下注射erenumab治疗慢性偏头痛，抗降钙素基因相关肽受体的单克隆抗体。虽然偏头痛没有反应，在使用erenumab治疗期间，患者的关节炎症状得到了显著改善；每日疼痛从VAS7降至2，步行距离从1,000m增加了一倍至2,000m。停用erenumab后，关节炎症状复发。Erenumab可能对骨关节炎的症状有潜在的有益作用。研究这些影响的未来研究是有必要的。
